种属反应性
human
包装
kit of 96 wells (12 strips x 8 wells)
技术
ELISA: suitable
capture ELISA: suitable
输入
sample type serum
sample type urine
sample type cell culture supernatant(s)
sample type plasma
assay range
inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 1 pg/mL
standard curve range: 1.23-900 pg/mL
检测方法
colorimetric
运输
wet ice
储存温度
−20°C
基因信息
human ... TNFRSF11B(4982)
一般描述
The Human Osteoprotegerin ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human Osteoprotegerin in serum, plasma, cell culture supernatants and urine.
Osteoprotegerin (OPG) is encoded by the gene mapped to human chromosome 8q24. It is a member of the TNFR (tumor necrosis factor receptor) superfamily that can act as a decoy receptor for RANKL (receptor activator of nuclear factor kappa-B ligand) and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand). OPG is expressed in a wide variety of tissues, including adult heart, lung, kidney and liver. It is secreted both as a monomeric and a dimeric protein.
Osteoprotegerin (OPG) is encoded by the gene mapped to human chromosome 8q24. It is a member of the TNFR (tumor necrosis factor receptor) superfamily that can act as a decoy receptor for RANKL (receptor activator of nuclear factor kappa-B ligand) and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand). OPG is expressed in a wide variety of tissues, including adult heart, lung, kidney and liver. It is secreted both as a monomeric and a dimeric protein.
免疫原
Recombinant Human OPG
应用
请参考Protocol了解详情。
生化/生理作用
Binding of soluble osteoprotegerin (OPG) to sRANKL (soluble receptor activator of nuclear factor κ-B ligand) inhibits osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells. This process leads to excess accumulation of bone and cartilage. Changes in the level of serum OPG are associated with atherosclerosis and cardiovascular disorders(CVDs). It might also be associated with malignancy and plays a regulatory role in multiple myeloma, prostate, breast, bladder and gastric carcinoma. OPG plays a vital role in bone metabolism and is involved in inhibition of ovariectomy-associated bone loss in rats. It is also used as a potent biomarker for CVD.
其他说明
A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.
Please type the word sample in the text box provided for lot number.
试剂盒组分也可单独购买
产品编号
说明
化学品安全说明书
警示用语：
Warning
危险声明
预防措施声明
危险分类
Met. Corr. 1
储存分类代码
8A - Combustible corrosive hazardous materials
法规信息
新产品
Roles and clinical applications of OPG and TRAIL as biomarkers in cardiovascular disease.
Bernardi S, et al.
BioMed Research International, 2016, 12-12 (2016)
Allison P Garcia et al.
Journal of clinical pharmacology, 60(2), 209-217 (2019-09-20)
This pilot study examined how exemestane (an aromatase inhibitor [AI]) affected osteoprotegerin (OPG) urine concentrations in postmenopausal women. Exemestane (25 mg, single dose) was given to 14 disease-free women past menopause in this nonrandomized, open-label study. Before dosing, urine specimens
Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.
Goswami S and Neelam S-W
BMC Cancer, 15(1), 935-935 (2015)
Functions of RANKL/RANK/OPG in bone modeling and remodeling.
Boyce BF and Xing L.
Archives of Biochemistry and Biophysics, 473(2), 139-146 (2008)
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet WS
Cell, 89(2), 309-319 (1997)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门